Vaxart, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
VXRT$0.550.0%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · Influenza Program Developments
Influenza Program Developments
| ● | In October 2026, Vaxart announced the publication of positive preclinical study results for its second-generation vaccine candidate, VXA-H5-02, against Highly Pathogenic Avian Influenza (HPAI) H5N1. The results demonstrated complete protection against a fatal dose of the current dominant virus strain. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.